Healthcare -
Drug Manufacturers - Specialty & Generic - NYSE - IN
$ 13.88
0 %
$ 11.6 B
Market Cap
18.23
P/E
1. INTRINSIC VALUE
Balance Sheet
Dr. Reddy's Laboratories Limited
| Current Assets | 248 B |
| Cash & Short-Term Investments | 81.5 B |
| Receivables | 80.3 B |
| Other Current Assets | 86.3 B |
| Non-Current Assets | 139 B |
| Long-Term Investments | 5.26 B |
| PP&E | 76.9 B |
| Other Non-Current Assets | 57.3 B |
| Current Liabilities | 96 B |
| Accounts Payable | 21.5 B |
| Short-Term Debt | 14 B |
| Other Current Liabilities | 60.5 B |
| Non-Current Liabilities | 10.9 B |
| Long-Term Debt | 5.99 B |
| Other Non-Current Liabilities | 4.94 B |
EFFICIENCY
Earnings Waterfall
Dr. Reddy's Laboratories Limited
| Revenue | 279 B |
| Cost Of Revenue | 116 B |
| Gross Profit | 164 B |
| Operating Expenses | 95.9 B |
| Operating Income | 67.7 B |
| Other Expenses | 12 B |
| Net Income | 55.7 B |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Dr. Reddy's Laboratories Limited
| Net Income | 55.7 B |
| Depreciation & Amortization | 14.8 B |
| Capital Expenditures | -27.4 B |
| Stock-Based Compensation | 821 M |
| Change in Working Capital | -20.2 B |
| Others | -15.6 B |
| Free Cash Flow | 18 B |
Wall Street Analysts Price Targets
Dr. Reddy's Laboratories Limited
RDY has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
0.00%
DIVIDEND YIELD
0.0958 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Dr. Reddy's Laboratories Limited
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
RDY & Bio-Thera Ink Deal for JNJ's Stelara/Simponi Biosimilar
Dr. Reddy's inks collaboration deal with Bio-Thera to develop and commercialize proposed biosimilar candidates of J&J's Stelara and Simponi in Southeast Asia.
zacks.com
- 1 month ago
Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia
GUANGZHOU, China and HYDERABAD, India , March 27, 2025 /PRNewswire/ -- Bio-Thera Solutions (688177:SH; "Bio-Thera"), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as "Dr. Reddy's"), announce today they have reached commercialization and license agreements for BAT2206, a proposed Stelara® biosimilar, and BAT2506, a proposed Simponi® biosimilar.
prnewswire.com
- 1 month ago
FDA Accepts RDY & ALVO's Prolia & Xgeva Biosimilar BLA for Review
Dr. Reddy and Alvotech announce the FDA acceptance of the BLA for their proposed biosimilar candidate of Amgen's Prolia and Xgeva for review.
zacks.com
- 1 month ago
Alvotech and Dr. Reddy's Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
HYDERABAD, India & REYKJAVIK, Iceland--(BUSINESS WIRE)---- $RDY #AVT03--Alvotech and Dr. Reddy's announce FDA acceptance of Biologic License Application for AVT03, a proposed biosimilar to Prolia® and Xgeva®.
businesswire.com
- 1 month ago
Dr. Reddy's Issues a Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, in the U.S., due to Mislabeling of Infusion Bag
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDYS--Dr. Reddy's issues a nationwide recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, due to mislabeling of infusion bag.
businesswire.com
- 1 month ago
Dr. Reddy's enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories SA today announced that it has entered into a license agreement with Henlius related to the commercialization of HLX15.
businesswire.com
- 2 months ago
Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.
SHANGHAI , Feb. 6, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as "Dr. Reddy's") for the company's independently developed investigational daratumumab biosimilar HLX15, a recombinant anti-CD38 fully human monoclonal antibody injection.
prnewswire.com
- 2 months ago
Dr. Reddy's Lab: Near-Term Worries And Underappreciated Potential Could Lead To Huge Returns
Dr. Reddy's Lab is undervalued due to exaggerated concerns about Revlimid revenue decline and the underappreciated potential of new high-growth products like biosimilars and GLP-1 drugs. Despite the anticipated Revlimid revenue drop, RDY's new product launches in biosimilars and GLP-1 segments are expected to offset losses, driving future growth. RDY's current P/E ratio of 17.7x is near historical lows; a conservative 23x PE, which is equal to the peer median and slightly lower than the median of the historical range.
seekingalpha.com
- 3 months ago
RDY Q3 Earnings Match Estimates, Generics Revenues Rise Y/Y, Stock Down
Dr. Reddy's stock falls on Q3 fiscal 2025 results, wherein earnings match estimates but revenues beat the same.
zacks.com
- 3 months ago
Dr. Reddy's Laboratories Limited (RDY) Q3 2025 Earnings Call Transcript
Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q3 2025 Earnings Conference Call January 23, 2025 9:00 AM ET Company Participants Richa Periwal – Head-Investor Relations and Analytics Erez Israeli – Chief Executive Officer M V Narasimham – Chief Financial Officer Conference Call Participants Kunal Dhamesha – Macquarie Neha Manpuria – Bank of America Amey Chalke – JM Financial Bino Pathiparampil – Elara Capital Surya Narayan Patra – PhillipCapital Damayanti Kerai – HSBC Tushar Manudhane – Motilal Oswal Financial Services Saion Mukherjee – Nomura Foram Parekh – Bank of Baroda Capital Market Anubhav Agrawal – UBS Vishal Manchanda – Systematix Shashank Krishnakumar – Emkay Global Operator Ladies and gentlemen, good day and welcome to the Quarter Three FY 2025 Earnings Conference Call of Dr. Reddy's Laboratories Limited. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes.
seekingalpha.com
- 3 months ago
Dr. Reddy's Q3 & 9MFY25 Financial Results
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #9MFY25--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter and nine months ended December 31, 2024.
businesswire.com
- 3 months ago
3 Emerging Market Stocks to Buy as 2024 Wraps Up
Here, we have picked three emerging market stocks, QFIN, YTRA and RDY, which are expected to show robust growth in 2025 on their growth strategies and fundamentals.
zacks.com
- 4 months ago
8. Profile
Summary
Dr. Reddy's Laboratories Limited RDY
COUNTRY
IN
INDUSTRY
Drug Manufacturers - Specialty & Generic
MARKET CAP
$ 11.6 B
Dividend Yield
0.00%
Description
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Contact
8-2-337, Road No. 3, Hyderabad, 500034
https://www.drreddys.com
IPO
Date
April 11, 2001
Employees
27048
Officers
Mr. Mannam Venkatanarasimham
Chief Financial Officer & Member of the Management Council
Mr. Venkata Ramana Motupalli M.B.A.
Chief Executive Officer of Branded Markets - India & Emerging Countries and Member of Management Council
Ms. Archana Bhaskar B.Sc., M.B.A.
EVice President, Head of Corporate Communications, Chief Human Resources Officer & Member of Management Council
Mr. Krishna K. Venkatesh B.Pharma M.S.
Global Head of Quality and Pharmacovigilance & Member of the Management Council
Mr. Deepak Sapra M.B.A.
Chief Executive Officer of API & Services & Member of Management Council
Mr. Sanjay Sharma B.Tech.
Executive Vice President, Global Head of Global Manufacturing & Member of Management Council
Mr. Patrick Aghanian B.A., M.B.A.
Chief Executive Officer of European Generics & Member of Management Council
Mr. Gunupati Venkateswara Prasad B.E.
Co-Chairman, MD & Member of Management Council
Mr. Kallam Satish Reddy B.Tech., M.S.
Chairman of the Board & Member of the Management Council
Mr. Erez Israeli M.B.A.
Chief Executive Officer & Member of the Management Council